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Summary
OBJECTIVES: In Switzerland, universal health insurance
does not cover any routine testing for sexually transmitted
infections (STIs), not even in individuals at high risk, and
extra-genital swabbing is not standard of care. We deter-
mined the prevalence and incidence of human immunod-
eficiency virus (HIV), viral hepatitis and non-viral STIs in a
multicentre prospective observational cohort of multi-part-
ner men who have sex with men (MSM) and other men.
MATERIALS AND METHODS: Between January 2016
and June 2017, we offered free STI testing to all men with
multiple sexual partners (three or more in the previous
12 months), with follow-up examinations every 6 months.
We used multiplex polymerase chain-reaction testing (for
Neisseria gonorrhoeae, Chlamydia trachomatis, Tri-
chomonas vaginalis, Mycoplasma genitalium) on pooled
swabs (pharynx, urethra/vagina, anus), and antibody tests
for HIV and Treponema pallidum at every visit, and for he-
patitis B/C at baseline.
RESULTS: We screened 779 multi-partner MSM and 92
other men. Previously undiagnosed HIV was found in
0.5% vs 0.0%, respectively and T. pallidum antibodies in
15.3% vs 1.1%. STIs requiring antibiotic treatment com-
prised: active syphilis 1.7% vs 0.0%; N. gonorrhoeae
10.3% vs 0.0%; C. trachomatis 8.7% vs 1.1%. One in four
MSM versus 1 in 100 other multi-partner men had any of
these three STIs at baseline. 10.4% vs 1.3% had a history
of hepatitis B, 31.9% vs 47.3% had no immunity (HBs-AB
<10 IU/l). Ten MSM had HCV antibodies (1.4%), with 8 out
of the 10 being MSM with HIV; HCV seroprevalence was
0.3% among HIV-negative MSM. In MSM, incidence of the
three bacterial STIs was 25.5 per year over 333 person
years of follow-up, HIV incidence was 0.3%. Non-condom-
use (in the last 3 months) for anal/vaginal sex was not as-
sociated with STIs. Independent risk factors were sex with
men (adjusted odds ratio [aOR] 16.4) and the number of
sexual partners (aOR 2.3 for >20).
CONCLUSION: Among MSM, but not among other multi-
partner men, STIs, mostly asymptomatic, are common.
Given the high risk of onward transmission, low-cost or
free routine screening of multi-partner MSM is a public
health priority.
Keywords: sexually transmitted diseases, men, sexual
and gender minorities, hepatitis C, hepatitis B, HIV, homo-
sexuality, sexual behaviour
Editorial note
We decided to publish the main results of the Swiss STAR
trial as two separate publications – one on the sub-sample
of men, another on the sub-sample of women. Reasons for
this include anatomical and epidemiological differences,
and the medical disciplines in charge: urology and infec-
tious diseases for men, and gynaecology for women. Fur-
thermore, the two main target groups, men who have sex
with men and female sex workers, differ with respect to
the legal and societal context of sexual contacts, all of
this probably resulting in distinct readerships. The detailed
joint methods for both publications are available as online
supplement.
Four key messages
1. In Switzerland five multi-partner MSM need screening
for bacterial STIs to find one with a notifiable and
clinically relevant infection: syphilis, gonorrhoea, or
chlamydia.
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2. Biannual STI screening among multi-partner MSM,
regardless of condom use, should be offered as part of
a free/low-cost package that also includes an HIV test.
3. In Switzerland, multi-partner men who only have sex
with women will not benefit from STI screening in
the absence of symptoms, or from regular routine HIV
testing.
4. In Switzerland, hepatitis C prevalence among non-
HIV-diagnosed MSM is low with no evidence for an
increasing trend.
Introduction
The Swiss National Programme on human immunodefi-
ciency virus (HIV) and other sexually transmitted infec-
tions (STIs) 2011–2017 highlights the importance of early
detection and correct treatment of STIs in addition to be-
havioural changes and vaccinations, where applicable [1].
Reducing numbers of sexual partners is a behavioural
change that likely results in a decreased risk of STIs [2],
although the role of condom use to prevent syphilis and
gonorrhoea, and particularly chlamydia, has been debated
[3–6].
The Swiss healthcare system, however, is a substantial bar-
rier to the implementation of this recommendation as uni-
versal health insurance does not cover any routine testing
for STIs, even in individuals at high risk. Although indi-
viduals with symptoms of an STI are likely to contact a
physician to receive appropriate treatment, asymptomatic
individuals may be reluctant to do so, since the costs for
STI screening have to be paid out of their own pocket.
If Swiss published recommendations are closely followed
and swabs from different anatomical sites are not pooled
[7], testing costs for syphilis, gonorrhoea, and chlamydia
add up to more than US$ 700 or, when adjusted for pur-
chasing power parity, of almost US$ 600 PPP [8]. Since
this characteristic of the Swiss healthcare system hinders
the implementation of a diagnostic procedure in the in-
terest of public health, the Swiss government is currently
investigating the implementation of a new financing sys-
tem for such diagnostic procedures. However, to establish
a system for the financing of these tests, the ideal target
group/s for such a diagnostic procedure need to be defined.
The prevalence and incidence of STIs in clients of testing
sites in Switzerland is largely unknown. The primary ob-
jective of the STAR trial was to describe the prevalence of
HIV and common non-viral STIs across different behav-
ioural/demographic risk categories. Although routine test-
ing for hepatitis C virus (HCV) in men who have sex with
men (MSM) without known HIV infection is not recom-
mended in Switzerland, studies have recommended close
monitoring of trends in the spread of HCV among MSM
[9]. For this reason, we included testing for HCV anti-
bodies as a secondary objective for MSM and female sex
workers (FSWs). Other secondary objectives were to de-
scribe the incidence of infections with HIV and common
non-viral STIs in MSM and FSWs, the prevalence of
chronic hepatitis B, and to compare self-reported with ac-
tual hepatitis B vaccination status / immunity. We aimed
to determine prevalence and incidence of HIV and STIs in
two groups considered at high risk for STIs: FSWs [10]
and MSM. This paper presents the results for MSM and a
small comparison group of multi-partner men who exclu-
sively had sex with women.
Materials and methods
Across Switzerland, between January 2016 and June 2017,
we offered free STI testing to men and women with mul-
tiple sexual partners (three or more in the last 12 months)
attending multiple STI testing sites. The study provided
follow-up examinations every 6 months. We used multi-
plex polymerase chain-reaction testing (PCR) (for Neis-
seria gonorrhoeae, Chlamydia trachomatis, Trichomonas
vaginalis, Mycoplasma genitalium) of pooled swabs (phar-
ynx, urethra/vagina, anus), and antibody tests for HIV and
Treponema pallidum (IgG/M, plus rapid plasma reagin if
positive) at every visit, and for hepatitis B and C at base-
line. At every visit, participants self-completed an anony-
mous online questionnaire. The detailed methods are de-
scribed in appendix 1.
Ethical approval was given on 21 July 2015 by the lead
ethics committee Eastern Switzerland (EKOS) under
BASEC PB_2016-00738, and subsequently approved by
ethics committees in Bern (KEK BE), Basel (EKNZ), Vaud
(CER-VD), and Zurich (KEK ZH).
Results
We enrolled 779 MSM (including 29 male sex workers)
and 92 other multi-partner men who reported sex exclu-
sively with women. Enrolment of male participants peaked
in summer 2016. Overall, 535 men returned at least once
for follow up, resulting in a follow-up rate of 61% and
338.0 person-years of follow-up. All participants received
all HIV/STI tests; five men were not tested for HBV, and
for 55 MSM HCV-RNA could not be determined because
one centre used the wrong sampling tubes; they were ex-
cluded from the respective analyses.
Sociodemographic characteristics
Participants from the French-speaking part of Switzerland
were over-represented. Most participants were recruited
in dedicated MSM health centres (‘Checkpoints’). Among
MSM, 0.3% were transgender men, 3.7% had sold sex
since their last HIV test and 3.6% had HIV diagnosed prior
to enrolment. Median age was 33 years for MSM vs 32
years among other multi-partner men. Nationality broad-
ly reflected the composition of the Swiss general popula-
tion. Almost all had health insurance in Switzerland. Al-
most half of MSM and about a third of other men were
single. Table 1 shows the sociodemographics.
Risk/precautionary behaviour
Overall, 78% of MSM vs 84.2% of other multi-partner
men reported full vaccination against hepatitis B. Human
papilloma virus (HPV) vaccination was reported by 4.1%
vs 1.4%, and in men under 27 by 8.3% vs 6.7%.
A history of previously diagnosed STIs was reported by
44.2% of MSM vs 17.4% of other multi-partner men. Fur-
thermore, 43.0% vs 10.9% had more than 10 partners in
the past 12 months; sex in a group was reported by 40.5%
vs 9.8%. Among MSM, two thirds had met at least half of
their partners online and 6.5% had paid for sex since their
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Persons with baseline visit N = 779 N = 92
Persons with follow-up visits n = 526 n = 9
Follow up visits n = 623 n = 9
Follow-up rate 526/779 (67.5) 9/92 (9.8)
Person years of follow up 333.2 years 4.8 years
Location of VCT centre in Switzerland French-speaking part 373/779 (47.9) 3/92 (3.3)
German-speaking part 406/779 (52.1) 89/92 (96.7)
Service recruited at Dedicated MSM health centre 593/779 (76.1) 4/92 (4.3)
General hospital 156/779 (20.0) 88/92 (95.7)
Other VCT centre 30/779 (3.9) 0/92 (0.0)
Sociodemographic parameters
Especially vulnerable groups Transgender (FtM) 2/779 (0.3) 0/92 (0.0)
Sold sex since last HIV test 29/779 (3.7) 0/92 (0.0)
Previously diagnosed HIV 28/779 (3.6) 0/92 (0.0)
Age <25 years 148/779 (19.0) 14/92 (15.2)
25–39 years 393/779 (50.4) 55/92 (59.8)
40+ years 238/779 (30.6) 23/92(25.0)
Median (IQR) 33 (26; 42) 32 (27; 40)
Nationality Swiss 543/779 (69.7) 85/92 (92.4)
Neighbouring countries: AT, DE, FR, IT 116/779 (14.9) 2/92 (2.2)
Latin American, ES, PT 53/779 (6.8) 0/92 (0.0)
Other Western European, US, CA 21/779 (2.7) 0/92 (0.0)
Eastern and South-eastern European 21/779 (2.7) 3/92 (3.3)
African 10/779 (1.3) 1/92 (1.1)
Asian 15/779 (1.9) 0/92 (0.0)
Unknown 0/779 (0.0) 1/92 (1.1)
Legal status Swiss 553/779 (69.7) 85/92 (92.4)
Settlement permit 99/779 (12.7) 3/92 (3.3)
Renewable/commuter permit 114/779 (14.6) 2/92 (2.2)
Short-term permit or tourist 18/779 (2.3) 2/92 (2.2)
No permit 5/779 (0.6) 0/92 (0.0)
Health insurance in Switzerland 734/764 (94.2) 89/91 (96.7)
Single / no steady partnership 356/751 (47.4) 33/92 (35.9)
Non-heterosexual identity* 757/779 (97.2) 0/92 (0.0)
Risk and precautionary behaviours
Reports hepatitis B vaccination† 462/592 (78.0) 48/57 (84.2)
Reports HPV vaccination† 25/609 (4.1) 1/74 (1.4)
Previous history of diagnosed STIs‡ 435/779 (44.2) 76/92 (17.4)
Number of sexual partners, previous 12 months 3–5 204/779 (26.2) 57/92 (62.0)
6–10 240/779 (30.8) 25/92 (27.2)
11–20 184/779 (23.6) 8/92 (8.7)
21–50 112/779 (14.4) 2/92 (2.2)
50+ 39/779 (5.0) 0/92 (0.0)
Bought sex since last HIV test 51/779 (6.5) 22/92 (23.9)
Sex in a group, previous 12 months No 464/779 (59.6) 83/92 (90.2)
Yes, longer than 6 weeks ago 298/779 (38.3) 9/92 (9.8)
Yes, in the last 6 weeks 17/779 (2.2) 0/92 (0.0)
Online acquisition of sex partners None, previous 12 months 132/779 (16.9) 51/92 (55.4)
Less than half, previous 12 months 129/779 (16.6) 26/92 (28.3)
Half or more, previous 12 months 518/779 (66.5) 15/92 (16.3)
PrEP use§ 8/779 (1.0) 0/92 (0.0)
CAVI, last 3 months 347/779 (44.5) 49/92 (46.7)
Negotiated safety No steady partner 356/749 (47.5) 33/92 (35.9)
No agreements 138/749 (18.4) 37/92 (40.2)
Condom use outside partnership 255/749 (34.0) 22/92 (23.9)
IDU, previous 12 months 4/773 (0.5) 0/88 (0.0)
Sexualised drug use¶ 235/743 (31.6) 14/89 (15.7)
Chemsex¶, previous 12 months 7/63 (11.1) n.a.
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AT = Austria; CA = Canada; CAVI = condomless anal or vaginal intercourse; DE = Germany; ES = Spain; FR = France; FtM = female to male transition; HIV = human immunodefi-
ciency virus; HPV = human papilloma virus; IDU = injection drug use; IQR = interquartile range; IT = Italy; MSM = men who have sex with men; PrEP = pre-exposure prophylaxis;
PT = Portugal; STI = sexually transmitted infection; US = United States of America; VCT = voluntary counselling and testing. * Identifying as homosexual, bisexual, or other (but
not as heterosexual) † Excluding participants who said they don’t know. ‡ It was not specified what counted as an STI (other than HIV). § PrEP use was the only variable not
self-reported but reported by medical staff. ¶ Sexualised drug use, consumption of poppers, cannabis, cocaine or synthetic drugs before or during sex; Chemsex, here defined as
use of GHB/GBL, ketamine, crystal methamphetamine, or mephedrone “often or always when having sex” in the previous 12 months.
last HIV test. Among other multi-partner men, 16.3% had
met at least half of their partners online and 23.9% had
paid for sex since their last HIV test.
About half of male participants (44.5% vs 46.7%) reported
condomless anal or vaginal intercourse in the past 3
months. Among respondents with a steady partner, MSM
were more likely to report explicit agreements on condom
use with non-steady partners (“negotiated safety”: 64.9%
vs 37.3%). Use of oral HIV chemoprophylaxis (PrEP) was
not included in the clients’ questionnaire but was docu-
mented for eight MSM (1.0%) at baseline.
Sexualised drug use was reported by 31.6% vs 15.7%. In-
jection drug use in the last 12 months was rare (0.5%
of MSM), but 11.1% reported Chemsex “often or always
when having sex”. Although the baseline measure for
Chemsex was based on only 63 participants, the follow-up
measure was similar (9.8% of N = 582). Table 1 shows risk
and precautionary behaviours.
Clinical outcomes: mental health, HIV/STIs, hepatitis
B and C
In both groups one third of men showed signs of major de-
pression in the PHQ-2 screening tool, and 11.9% of MSM
vs 4.3% of other multi-partner men were sexually unhappy
(p = 0.015).
Previously undiagnosed HIV was found in 0.5% vs 0.0%
and T. pallidum antibodies in 15.3% vs 1.1% (p <0.001).
For STIs requiring antibiotic treatment according to some
guidelines at the time, we found active syphilis in 1.4%
vs 0.0%, N. gonorrhoeae in 10.3% vs 0.0% (p <0.001), C.
trachomatis in 8.7% vs 1.1% (p = 0.003), T. vaginalis in
3.2% vs 2.2% and M. genitalium in 5.3% vs 1.1% (p =
0.051). The collective measure for any of those five STIs
was 25.6% vs 4.4%, corresponding to a number needed to
screen (NNS) of 4 vs 23 (p <0.001).
When only bacterial infections with N. gonorrhoeae, C.
trachomatis, and T. pallidum were considered to require
treatment, the number needed to screen among MSM was
still low (one in five), vs one in a hundred among other
multi-partner men (p <0.001).
For viral hepatitis, 10.4% of MSM vs 1.3% of other multi-
partner men had a history of hepatitis B (antibodies to he-
patitis B core antigen [HBc-AB] positive, p = 0.003), 1.4%
vs 1.3% had chronic hepatitis B (HBc-AB positive, anti-
bodies to hepatitis B surface antigen [HBs-AB] negative)
and 31.9% vs 47.3% had no immunity (HBs-AB <10 IU/l,
p = 0.003). Among MSM, with use of this HBs-AB cut-off,
the question relating to hepatitis B vaccination was 89.7%
sensitive and 44.7% specific. Ten MSM had HCV antibod-
ies (1.4%), with 8 out of the 10 being MSM with HIV;
HCV seroprevalence was 0.6% among MSM without HIV
infection known at baseline, and 0.3% among HIV-nega-
tive MSM. Three MSM (0.4%) had detectable HCV-RNA
– all of them also had HIV. Table 2 shows the clinical out-
comes.
Despite a rather small control group, the differences were
statistically significant for a history of syphilis, current
gonorrhoea, currant C. trachomatis infection, and for all
combined outcomes. The differences were also statistically
significant for a history of hepatitis B and lack of corre-
sponding immunity.
Among MSM, with over 333.2 person years of follow-up,
the proportion with incident STIs over 1 year of follow-
up was slightly higher than prevalent STIs at baseline (fig.
1), but only the aggregated measure of “any of the five
STIs” showed a significantly higher incidence. We found
one incident HIV infection, corresponding to an incidence
of 0.3%.
Multivariable models
In multivariable regression analysis (table 3) – further con-
trolling for age, previous HIV status, transactional sex and
group sex – inconsistent condom use (in the last 3 months)
for anal/vaginal sex was not associated with STIs (neither
was “negotiated safety”, data not shown). Independent risk
factors were sex with men (adjusted odds ratio [aOR] 16.4,
95% confidence interval [CI] 2.4–120.1) and the number
of sexual partners (aOR 2.3 for >20, 95% CI 1.2–4.5).
When also controlled for reported symptoms, our findings
were largely similar, but the variance explained by our
model increased from 10% to 13%. Using alternative com-
posite outcomes by adding M. genitalium and T. vaginalis
did not substantially challenge these findings; however all
effect size measures decreased and so did the explained
variance.
Discussion
Among multi-partner MSM, but not among other multi-
partner men, STIs, mostly asymptomatic, are common. In
voluntary counselling and testing centres in Switzerland
five multi-partner MSM need to be screened for bacterial
STIs to find one with a notifiable and clinically relevant
infection: syphilis, gonorrhoea, or chlamydia. One in four
MSM acquired at least one of these bacterial STIs per year.
Given that less than 4% of MSM had previously diagnosed
HIV at baseline – less than half of what would have been
expected [11] – our estimates may be conservative.
HIV
We found an HIV incidence of 0.3% per year in MSM,
matching previous findings based on MSM population es-
timates and notification data [11, 12]. The baseline preva-
lence of previously undiagnosed HIV in MSM was similar
(0.5%), suggesting HIV testing is frequent in this popula-
tion.
Hepatitis B and C
This study confirms previous findings that HCV infections
are concentrated in HIV-diagnosed MSM, but among
MSM without diagnosed HIV do not exceed the preva-
lence in the general population. When results of the two
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published studies on HCV in non-HIV-diagnosed MSM
in Switzerland (total n = 1454) are combined, HCV sero-
prevalence was 0.3% (95% CI 0.1–0.7) and HCV-RNA
was present in 0.1% (95% CI 0.01–0.4) [9].This is not sta-
tistically different from our findings, with 0.3% (0.05–1.2)
and 0.0% (0.0–0.4), respectively. It also suggests that be-
tween 2009 and 2016, HCV in non-HIV-diagnosed MSM
in Switzerland has not increased.
In Switzerland, hepatitis B vaccination is recommended
and reimbursed for all adolescents as well as men and
women with “frequently changing partners” [13]. All study
participants were eligible for hepatitis B vaccination. Al-
though previous hepatitis B infection correlated positively
with age, MSM had an overall prevalence of 10% of HBc-
AB, much higher than among other multi-partner men,
which suggests the promotion of hepatitis B vaccination
among MSM should be prioritised. A third of MSM
showed evidence of no or insufficient vaccination, despite
a conservative cut-off of <10 IU/l. Whereas the question on
self-reported hepatitis B vaccination showed a high sensi-
tivity for detecting individuals with previous vaccination,
it was not very specific and thus overestimates true vacci-
nation status. This has implications for monitoring vacci-
nation coverage.
Non-viral STIs
Fifteen per cent of MSM showed evidence of prior syphilis
infection, matching the 15.4% reported in one of the largest
studies of MSM living in Switzerland (EMIS-2017) [14]
After a historic nadir around the year 2000, syphilis inci-
dence has steadily increased [15]. Epidemiological models
have suggested that even sustainable interventions around
partner reduction or increasing condom use would have
limited effects [16], and the US Centers for Disease Con-
trol’s syphilis elimination plan officially ended in 2013
[17]. Among MSM in this study, the baseline prevalence
of active syphilis was 1.7%, and the incidence was 4.2 per
Table 2: Clinical outcomes. Mental health, HIV, STIs, Hepatitis B and C, percentages with 95% confidence intervals.




Persons with baseline visit n = 779 n = 92
Mental Health Sexually unhappy 11.9 (9.8–14.5) 4.3 (1.4–11.4)
Signs of major depression (PHQ-2 variant) 31.8 (28.6–35.3) 31.5 (22.5–42.2)
HIV Newly diagnosed HIV 0.5 (0.2–1.4) 0.0 (0.0–3.3)
STIs Active syphilis (treatment) 1.7 (0.9–2.9) 0.0 (0.0–3.3)
T. pallidum IgG/M positive 15.3 (12.9–18.0) 1.1 (0.1–6.8)
High RPR/VDRL (reactive at 1: ≥8) 1.3 (0.7–1.4) 0.0 (0.0–3.3)
N. gonorrhoeae 10.3 (8.3–12.7) 0.0 (0.0–3.3)
C. trachomatis 8.7 (6.9–11.0) 1.1 (0.1–6.8)
T. vaginalis 3.2 (2.1–4.8) 2.2 (0.4–8.4)
M. genitalium 5.3 (3.8–7.1) 1.1 (0.1–6.8)
Active syphilis, NG, or CT 19.0 (16.3–22.0) 1.1 (0.1–6.8)
Active syphilis, NG, CT, or TV 21.4 (18.6–24.5) 3.3 (0.8–9.9)
Active syphilis, NG, CT, TV, or MG 25.5 (22.5–28.8) 4.3 (1.4–11.4)
Reporting STI symptoms* 15.0 (12.6–17.7) 12.0 (6.4–20.8)
Hepatitis B and C No. persons with HBs-AB (HBc-AB, HCV-AB) n = 775 (511, 724) n = 91 (77, n.a.)
HBs-AB <10 IU/l 31.9 (28.6–35.3) 47.3 (36.8–57.9)
HBc-AB positive 10.4 (8.0–13.5) 1.3 (1.2–6.7)
HBc-AB positive, HBs-AB negative 1.4 (0.6–3.0) 1.3 (0.1–8.1)
HCV-AB 1.4 (0.8–2.7) n.a.
HCV-RNA 0.4 (0.1–1.3) n.a.
HCV-AB among HIV-negative 0.3 (0.05–1.2) n.a.
HCV-RNA among HIV-negative 0.0 (0.0–0.4) n.a.
Yearly incidence during follow-up MSM
% (95% CI)
Persons with follow-up visits n = 526
Follow up visits n = 623
Person-years of follow up 333.2 years
HIV Newly diagnosed HIV 0.3 (0.04–2.2)
STIs Active syphilis (treatment) 4.2 (2.5–7.0)
High RPR/VDRL (reactive at 1: ≥8) 2.1 (1.0–4.4
N. gonorrhoeae 14.7 (11.4–19.0)
C. trachomatis 9.0 (6.4–12.7)
T. vaginalis 5.4 (3.4–8.5)
M. genitalium 6.3 (4.2–9.5)
Active syphilis, NG, or CT 25.5 (21.2–30.6)
Active syphilis, NG, CT, or TV 30.6 (26.0–36.0)
Active syphilis, NG, CT, TV, or MG 36.9 (32.1–42.5)
AB = antibodies; CI = confidence interval; CT = C. trachomatis; MSM = men who have sex with men; HBc = hepatitis B core; HBs = hepatitis B surface; HBV = hepatitis B virus;
HCV = hepatitis C virus; HIV = human immunodeficiency virus; IgG/M = immunoglobulin G/M; IU = international units; MG = M. genitalium; MSM = men who have sex with men;
NG = N. gonorrhoeae; PHQ = patient health questionnaire; RPR = rapid plasma reagin; STI = sexually transmitted infection; TV = T. vaginalis; VDRL = venereal diseases research
laboratory. * Participants were shown a comprehensive list of STI symptoms and asked if they currently had any of them.
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100 person-years. This compares to 74 per 100 person-
years among HIV-positive MSM in the Swiss HIV Cohort
Study in 2014 [18], corroborating previous findings that
the current syphilis epidemic is concentrated in sexual net-
works of MSM in general, and in sexual networks of HIV-
positive MSM in particular. Given that syphilis incidence
Figure 1: Sexually transmitted infections among men who have sex with men at baseline (n = 779) and during follow-up (n = 526 over 623 fol-
low-up visits; 333.2 years of follow-up); percent with 95% confidence intervals. CT = C. trachomatis; MG = M. genitalium; NG = N. gonor-
rhoeae; TV = T. vaginalis.
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in this study was 10 times higher than HIV incidence,
we agree with Australian guidelines that testing MSM for
syphilis only once per year may not be sufficient to control
the epidemic [19].
As urethral infections with N. gonorrhoeae are typically
symptomatic and lead to medical consultation [20], most
cases of gonorrhoea in this study are likely to have been
present in the rectum, and/or in the oropharynx. The major-
ity of N. gonorrhoeae / C. trachomatis infections in MSM
are missed if asymptomatic testing is restricted to a urine
specimen [21]. Pharyngeal screening is not implemented
in many national guidelines, but the contribution of fella-
tio to transmission of not only N. gonorrhoeae but also C.
trachomatis has been demonstrated [4]. This means all N.
gonorrhoeae / C. trachomatis detected in this study would
likely contribute to onward transmission if left untreated,
as self-clearance of asymptomatic infections takes longer
(>100 days) [22] than the time to the next sexual encounter
– at least on average in MSM with three or more partners
per year.
It has been proposed that C. trachomatis infection control
programmes based on early detection and treatment might
interfere with the effects of immunity on population sus-
ceptibility to infection. The same authors suggest two
strategies to decrease C. trachomatis infections at the pop-
ulation level: developing a vaccine or strategies to alter
sexual networks [23]. Whereas in settings with low C. tra-
chomatis prevalence (e.g., <5% in young adults), oppor-
tunistic testing may not result in “sizeable reductions” in
chlamydia prevalence [24]; C. trachomatis prevalence was
higher in this and other studies [25] of MSM, and asympto-
matic rectal chlamydial infections in MSM have been pro-
posed as an important reservoir fuelling transmission [26].
As 90% (unpublished data FOPH) of N. gonorrhoeae / C.
trachomatis diagnoses in Switzerland are based on nucleic
acid amplification technique (NAAT), it would also be dif-
ficult to screen for gonorrhoea alone.
Infections with T. vaginalis among MSM were not uncom-
mon, although less frequent than N. gonorrhoeae / C. tra-
chomatis and not significantly higher than in other multi-
partner men. Other research has suggested that T. vaginalis
may circulate within MSM networks and not result from
concurrent sexual contact with women [27]. Our multi-
variable model suggests that transmission of T. vaginalis
(and M. genitalium) is less specific to MSM, and less de-
pendent on typical STI determinants such as the num-
ber of sexual partners. Given the substantial side-effects
of metronidazole (standard treatment for T. vaginalis), the
high rates of antimicrobial resistance of M. genitalium, and
the unclear public health impact of infections with T. vagi-
nalis / M. genitalium, we do not recommend routine test-
ing of men for T. vaginalis or M. genitalium. M. genitalium
will be analysed in a subsequent paper.
Risk and precautionary behaviour
Slightly more than half of men reported consistent condom
use for anal or vaginal sex, with no significant difference
between the two groups. In Switzerland at the time of
enrolment, PrEP was recommended for men and women
at high risk for HIV [28], but not implemented and only
available through online importation. Two years later, 4%
of HIV-negative MSM reported current PrEP use [29], two
thirds of them accessing PrEP informally online [14].
MSM reported much higher numbers of sexual partners
than other multi-partner men. The distribution of partner
numbers in the last 12 months almost perfectly reflected
EMIS-2017 results, when the Swiss EMIS-2017 data was
restricted to the sub-sample to men with 3+ partners (two
thirds of the total): 3–10 partners, 62% (STAR) vs 56%
(EMIS-2017); 11–20 partners, 19% vs 23%; 21–50 part-
ners, 14% vs 14%, 50+ partners, 6% vs 7% [14]. Contrast-
ingly, the majority of heterosexual men in STAR had only
3 to 5 sexual partners in the previous 12 months, but they
were much more likely to report having paid for sex when
compared with MSM.
Group sex and sexualised drug use were common among
MSM. The proportion of MSM engaging in Chemsex was
similar to other recently published studies from Switzer-
land – for example, the 11.8% of EMIS-2017 respondents
in Switzerland reporting stimulant drugs in the last 12
months [14], or the 7.9% based on the same online tool
but with a much larger sample size [30]. The difference
from the latter publication might be attributable to our re-
striction to multi-partner men. What these studies have in
common is the anonymous nature of reporting illicit/stig-
matised behaviour. Surprisingly, Chemsex figures were not
higher among HIV-positive MSM in the Swiss HIV Co-
hort Study [31], possibly indicating under-reporting of il-
licit/stigmatised behaviour in a clinical interview setting.
Since 2016, HPV vaccination has been recommended and
reimbursed also for boys and men younger than 27 [32]. A
result of 7% to 8% self-reported coverage among men in
the eligible age group is an excellent outcome for the first
year of implementation for men.
Strengths and limitations
The strengths of this study include the large sample size of
MSM, the high rate of follow-up, and the rigorous method-
ology with respect to comprehensive STI testing. The
study was sufficiently powered to detect even rare infec-
tions such as hepatitis C. The study participants represent-
ed a broad range of men with respect to age, nationality,
legal status and place of residence. Although the coun-
try’s Italian-speaking part was clearly under-represented,
we think that our MSM results are largely representative
for sexually active gay and bisexual men in Switzerland.
This study has several limitations. It was not sufficiently
powered to calculate the incidence of STIs among multi-
partner men who exclusively have sex with women. The
pooling of meatal/urethral, anal and pharyngeal swabs pre-
cludes the possibility of calculating site-specific preva-
lences, and also might lead to an underestimation of pha-
ryngeal and thus overall N. gonorrhoeae infections [33].
Another major limitation is the absence of any test of cure.
However, we think it is unlikely that syphilis, N. gonor-
rhoeae or C. trachomatis were not cured by standard treat-
ment. Persisting infections would lead to an overestimation
of incident cases, which is one of the reasons for not in-
cluding MG or TV in our main outcome variable for inci-
dent STIs.
It needs to be highlighted that all behavioural data were
self-reported. The finding that condom use was not protec-
tive against STIs (fig. S2 in appendix 1) has to be inter-
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preted with caution. However, oral sex in MSM is typically
condom-free – both fellatio [34] and oro-anal sex [35]. Al-
though condoms effectively prevent contact with ejaculate,
their effect of reducing mucosal contact over the whole
course of sexual encounters is limited. In the common sce-
nario of anal fingering prior to intercourse, transmission of
STIs is possible via smear infection before or at the time of
condom application.
Implications
The high incidence-to-prevalence ratio of the combined
endpoint (active syphilis, gonorrhoea, or chlamydia) sug-
gests that annual screening may be insufficient to control
the epidemic of these three STIs in MSM. Biannual screen-
ing might be more adequate as a standard for multi-partner
MSM [36], particularly for those with more than 10 part-
ners per year. Other research has also suggested specifying
situations in which culture-based testing is needed to pro-
vide information about anti-microbial resistance in N. gon-
orrhoeae [20]. Given the high prevalence and incidence
of gonorrhoea among multi-partner MSM, this population
is a good target for additional culture testing, with costs
borne by the health care system rather than by the client.
The best testing frequency MSM still needs to be deter-
mined by mathematical modelling, and in Switzerland the
online counselling tool used in voluntary counselling and
testing centres could include an algorithm to estimate the
best individual interval for repeat testing based on personal
data. Routine testing of heterosexual multi-partner men is
not supported by our findings. Being part of a dense sexual
network with a high turn-over of sexual partners may have
a much larger impact on STI transmission than individual
sexual behaviour [37, 38].
Conclusions
This study supports previous recommendations for MSM
that syphilis testing and nucleic acid amplification technol-
ogy-based screening for N. gonorrhoea (combined with C.
trachomatis) at extra-genital sites [25] should be widely
available, and providers should be educated about appro-
priate screening practice [19, 39, 40]. However, recom-
mending regular testing in asymptomatic multi-partner in-
dividuals for the benefit of public health is pointless if it
is not affordable to those at risk. MSM at highest risk of
infection would have to spend more than US$ 2000 PPP
[8] per year if screened for example every 3 months. The
current price system in Switzerland may lead to substan-
tial undertesting [20] and thus impede STI control among
MSM. Given the high risk of onward transmission of bac-
terial STIs, low-cost or free routine screening of multi-
partner MSM is a public health priority.
Preliminary data of this study were presented at the 31st
annual IUSTI Europe conference in Helsinki, Finland
(IUSTI17-47, IUSTI17-53) in August/September 2017, and
at the Swiss HIV&STI Forum in March 2018.
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Appendix 1: Methods in detail
The appendix is available as a separate file at
https://smw.ch/article/doi/smw.2020.20392.
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